FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
FATE on Nasdaq
Shares outstanding
114,331,829
Price per share
$0.98
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
80,482,515
Total reported value
$101,400,876
% of total 13F portfolios
0%
Share change
+1,171,948
Value change
+$1,893,585
Number of holders
137
Price from insider filings
$0.98
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 15% 0% $18,659,242 +$129,943 17,941,579 +0.7% Redmile Group, LLC 02 Jul 2025
VANGUARD GROUP INC 7.6% $9,117,435 8,766,764 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 6.9% $7,145,487 7,852,183 BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 2% -77% $2,546,902 -$6,958,784 2,274,020 -73% THE GOLDMAN SACHS GROUP, INC. 30 Jun 2025
Schonfeld Strategic Advisors LLC 0.82% -85% $1,050,024 -$7,679,831 937,521 -88% Schonfeld Strategic Advisors LLC 30 Jun 2025

As of 30 Sep 2025, 137 institutional investors reported holding 80,482,515 shares of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE). This represents 70% of the company’s total 114,331,829 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) together control 63% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Redmile Group, LLC 11% 12,872,946 0% 1.6% $16,219,912
BlackRock, Inc. 9.3% 10,680,727 -1.2% 0% $13,457,714
VANGUARD GROUP INC 7.7% 8,798,491 +0.36% 0% $11,086,098
Wilshire Advisors LLC 7.4% 8,486,822 28% $10,693,396
JOHNSON & JOHNSON 3% 3,379,064 0% 0.85% $4,257,621
ACADIAN ASSET MANAGEMENT LLC 2.4% 2,710,234 +10% 0.01% $3,412,000
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,530,212 +4.2% 0% $3,188,561
Vestal Point Capital, LP 2.2% 2,515,000 0% 0.14% $3,168,900
STATE STREET CORP 2.1% 2,417,135 +8.4% 0% $3,045,590
DIMENSIONAL FUND ADVISORS LP 1.8% 2,094,975 -14% 0% $2,637,886
TANG CAPITAL MANAGEMENT LLC 1.6% 1,867,773 0% 0.09% $2,353,394
GOLDMAN SACHS GROUP INC 1.3% 1,486,407 -41% 0% $1,872,873
RENAISSANCE TECHNOLOGIES LLC 1.1% 1,262,515 +489% 0% $1,590,769
AQR CAPITAL MANAGEMENT LLC 0.99% 1,131,414 +34% 0% $1,425,581
TWO SIGMA ADVISERS, LP 0.88% 1,007,400 +104% 0% $1,269,324
MILLENNIUM MANAGEMENT LLC 0.84% 963,871 +9.6% 0% $1,214,477
MORGAN STANLEY 0.81% 929,944 -62% 0% $1,171,730
TWO SIGMA INVESTMENTS, LP 0.79% 900,757 +294% 0% $1,134,954
CITADEL ADVISORS LLC 0.72% 824,545 -82% 0% $1,038,927
JACOBS LEVY EQUITY MANAGEMENT, INC 0.71% 814,639 -33% 0% $1,026,445
NORTHERN TRUST CORP 0.71% 814,465 -3.5% 0% $1,026,226
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.69% 785,921 +7.1% 0% $990,260
Monaco Asset Management SAM 0.67% 770,000 +14% 0.36% $970,200
Bruce & Co., Inc. 0.64% 729,188 +70% 0.28% $918,777
Woodline Partners LP 0.62% 712,650 0% 0% $897,939

Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 320,565 $315,709 +$20,876 $0.98 12
2025 Q3 80,482,515 $101,400,876 +$1,893,585 $1.26 137
2025 Q2 79,555,724 $88,833,451 -$17,593,208 $1.12 136
2025 Q1 96,451,503 $76,210,242 -$16,246,817 $0.79 127
2024 Q4 100,739,780 $166,212,161 -$49,327,616 $1.65 154
2024 Q3 114,626,757 $401,134,054 -$26,316,226 $3.50 157
2024 Q2 122,172,970 $400,716,308 -$37,556,595 $3.28 175
2024 Q1 122,958,805 $902,517,367 +$212,488,805 $7.34 161
2023 Q4 193,112 $722,239 +$416,228 $3.74 3
2023 Q3 95,655,546 $202,786,096 -$40,803,419 $2.12 162
2023 Q2 108,822,065 $518,024,328 -$20,807,671 $4.76 180
2023 Q1 112,518,494 $641,342,957 -$47,825,503 $5.70 174
2022 Q4 104,009,111 $1,049,453,038 -$66,024,092 $10.09 217
2022 Q3 107,404,167 $2,404,339,534 -$56,462,362 $22.41 218
2022 Q2 108,871,060 $2,676,352,768 +$193,664,385 $24.78 207
2022 Q1 100,983,215 $3,912,460,118 +$152,790,990 $38.77 230
2021 Q4 96,052,562 $5,620,175,833 +$807,576 $58.51 235
2021 Q3 95,692,352 $5,670,094,859 +$43,175,038 $59.27 255
2021 Q2 93,765,446 $8,135,977,027 +$47,058,197 $86.79 265
2021 Q1 93,746,285 $7,730,722,264 +$547,330,107 $82.45 253
2020 Q4 82,453,953 $7,497,666,923 -$82,746,293 $90.93 240
2020 Q3 87,474,883 $3,495,766,003 +$83,736,429 $39.97 205
2020 Q2 85,661,068 $2,937,178,994 +$358,135,234 $34.31 197
2020 Q1 75,606,763 $1,679,422,294 +$78,807,544 $22.21 153
2019 Q4 72,204,195 $1,413,020,139 -$7,630,391 $19.57 144
2019 Q3 72,139,790 $1,120,300,451 +$167,966,990 $15.53 144
2019 Q2 62,185,664 $1,262,414,068 +$61,724,565 $20.30 132
2019 Q1 59,528,445 $1,045,911,832 +$39,198,800 $17.57 119
2018 Q4 57,348,458 $735,728,973 +$35,311,691 $12.83 120
2018 Q3 54,831,196 $890,578,545 +$191,331,313 $16.29 113
2018 Q2 43,037,848 $488,051,307 +$35,445,934 $11.34 101
2018 Q1 39,404,544 $384,590,041 +$46,886,960 $9.76 87
2017 Q4 35,345,824 $214,129,408 +$65,332,083 $6.11 77
2017 Q3 25,399,194 $100,587,735 -$4,412,768 $3.96 69
2017 Q2 26,601,858 $86,189,950 +$4,817,787 $3.24 56
2017 Q1 25,004,554 $113,767,000 +$8,813,323 $4.55 50
2016 Q4 23,128,984 $57,885,000 +$8,803,527 $2.51 33
2016 Q3 19,481,982 $60,781,000 +$17,053,440 $3.12 36
2016 Q2 14,071,764 $23,921,000 -$3,096,742 $1.70 37
2016 Q1 15,773,542 $28,394,000 -$9,461,152 $1.80 42
2015 Q4 18,614,016 $62,724,000 -$726,308 $3.37 51
2015 Q3 18,349,000 $97,801,000 +$1,769,404 $5.33 41
2015 Q2 17,989,173 $116,386,000 +$47,813,640 $6.47 36
2015 Q1 10,608,782 $51,875,000 +$1,628,435 $4.89 25
2014 Q4 10,275,305 $51,680,000 -$3,435 $5.02 23
2014 Q3 10,270,522 $52,580,000 +$2,084,892 $5.10 22
2014 Q2 9,853,337 $62,410,000 +$1,716,798 $6.31 21
2014 Q1 9,563,610 $92,835,964 +$30,694,456 $9.74 21